Researchers say GLP-1 medicines might be able to help with migraines.

Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...

A mother-of-three who shed two stone in just nine weeks thanks to a skinny jab has warned users of a painful side-effect that ...

Benefit managers will need to modernize their strategies and offerings around well-being, caregiving and professional ...

Fibromyalgia patients taking GLP-1s have lower rates of opioid use, pain, fatigue, and malaise in a real-world patient data ...

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that it will host an investor event at the Endocrine Society’s annual meeting (ENDO 2025) on Sunday, July 13, ...

Several top nutrition and obesity organizations provided the first unified guidelines for helping patients manage their ...

The rise of Ozempic and weight-loss drugs is a convenient excuse for the fashion industry and retailers to cut back on plus-size clothing options.

Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

Walmart's valuation may be overhyped amidst industry headwinds and risks like SNAP cuts, tariffs, and shifting consumer ...

We spoke with Tahiri about the evolution of nutrition innovation, the importance of understanding consumers on a deeper level ...